Skip to main content
Top
Published in: Diabetologia 12/2003

01-12-2003 | Article

Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI

Authors: T. den Heijer, S. E. Vermeer, E. J. van Dijk, N. D. Prins, P. J. Koudstaal, A. Hofman, Dr. M. M. B. Breteler

Published in: Diabetologia | Issue 12/2003

Login to get access

Abstract

Aim/hypothesis

Type 2 diabetes increases the risk not only of vascular dementia but also of Alzheimer’s disease. The question remains whether diabetes increases the risk of Alzheimer’s disease by diabetic vasculopathy or whether diabetes influences directly the development of Alzheimer neuropathology. In vivo, hippocampal and amygdalar atrophy on brain MRI are good, early markers of the degree of Alzheimer neuropathology. We investigated the association between diabetes mellitus, insulin resistance and the degree of hippocampal and amygdalar atrophy on magnetic resonance imaging (MRI) accounting for vascular pathology.

Methods

Data was obtained in a population-based study of elderly subjects without dementia between 60 to 90 years of age. The presence of diabetes mellitus and, in non-diabetic subjects, insulin resistance was assessed for 506 participants in whom hippocampal and amygdalar volumes on MRI were measured. We assessed the degree of vascular morbidity by rating carotid atherosclerosis, and brain white matter lesions and infarcts on MRI.

Results

Subjects with diabetes mellitus had more hippocampal and amygdalar atrophy on MRI compared to subjects without diabetes mellitus. Furthermore, increasing insulin resistance was associated with more amygdalar atrophy on MRI. The associations were not due to vascular morbidity being more pronounced in persons with diabetes mellitus.

Conclusions/interpretation

Type 2 diabetes is associated with hippocampal and amygdalar atrophy, regardless of vascular pathology. This could suggest that Type 2 diabetes directly influences the development of Alzheimer neuropathology.
Literature
1.
go back to reference Goldstein LB, Adams R, Becker K et al. (2001) Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103:163–182PubMed Goldstein LB, Adams R, Becker K et al. (2001) Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103:163–182PubMed
2.
go back to reference Hébert R, Lindsay J, Verreault R et al. (2000) Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 31:1487–1493PubMed Hébert R, Lindsay J, Verreault R et al. (2000) Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 31:1487–1493PubMed
3.
go back to reference Ott A, Stolk RP, van Harskamp F et al. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53:1937–1942PubMed Ott A, Stolk RP, van Harskamp F et al. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53:1937–1942PubMed
4.
go back to reference Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262PubMed Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262PubMed
5.
go back to reference Snowdon DA, Greiner LH, Mortimer JA et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817PubMed Snowdon DA, Greiner LH, Mortimer JA et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817PubMed
6.
go back to reference Vitek MP, Bhattacharya K, Glendening JM et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91:4766–4770PubMed Vitek MP, Bhattacharya K, Glendening JM et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91:4766–4770PubMed
7.
go back to reference Gasparini L, Netzer WJ, Greengard P et al. (2002) Does insulin dysfunction play a role in Alzheimer’s disease? Trends Pharmacol Sci 23:288–293PubMed Gasparini L, Netzer WJ, Greengard P et al. (2002) Does insulin dysfunction play a role in Alzheimer’s disease? Trends Pharmacol Sci 23:288–293PubMed
8.
go back to reference Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMed Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMed
9.
go back to reference Gosche KM, Mortimer JA, Smith CD et al. (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482PubMed Gosche KM, Mortimer JA, Smith CD et al. (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482PubMed
10.
go back to reference Convit A, De Leon MJ, Tarshish C et al. (1997) Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 18:131–138PubMed Convit A, De Leon MJ, Tarshish C et al. (1997) Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 18:131–138PubMed
11.
go back to reference Jack CR Jr, Petersen RC, Xu YC et al. (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397–1403PubMed Jack CR Jr, Petersen RC, Xu YC et al. (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397–1403PubMed
12.
go back to reference Schott JM, Fox NC, Frost C et al. (2003) Assessing the onset of structural change in familial Alzheimer’s disease. Ann Neurol 53:181–188CrossRefPubMed Schott JM, Fox NC, Frost C et al. (2003) Assessing the onset of structural change in familial Alzheimer’s disease. Ann Neurol 53:181–188CrossRefPubMed
13.
go back to reference Callen DJ, Black SE, Gao F et al. (2001) Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology 57:1669–1674PubMed Callen DJ, Black SE, Gao F et al. (2001) Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology 57:1669–1674PubMed
14.
go back to reference Krasuski JS, Alexander GE, Horwitz B et al. (1998) Volumes of medial temporal lobe structures in patients with Alzheimer’s disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry 43:60–68 Krasuski JS, Alexander GE, Horwitz B et al. (1998) Volumes of medial temporal lobe structures in patients with Alzheimer’s disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry 43:60–68
15.
go back to reference Hofman A, Grobbee DE, de Jong PTVM et al. (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7:403–422PubMed Hofman A, Grobbee DE, de Jong PTVM et al. (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7:403–422PubMed
16.
go back to reference Breteler MMB (2000) Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 903:457–465PubMed Breteler MMB (2000) Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 903:457–465PubMed
17.
go back to reference Ott A, Stolk RP, Hofman A et al. (1996) Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39:1392–1397PubMed Ott A, Stolk RP, Hofman A et al. (1996) Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39:1392–1397PubMed
18.
go back to reference de Leeuw FE, de Groot JC, Oudkerk M et al. (1999) A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 46:827–833PubMed de Leeuw FE, de Groot JC, Oudkerk M et al. (1999) A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 46:827–833PubMed
19.
go back to reference de Groot JC, de Leeuw FE, Oudkerk M et al. (2000) Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47:145–151CrossRefPubMed de Groot JC, de Leeuw FE, Oudkerk M et al. (2000) Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47:145–151CrossRefPubMed
20.
go back to reference Hackert VH, den Heijer T, Oudkerk M et al. (2002) Hippocampal head size associated with verbal memory performance in nondemented elderly. Neuroimage 17:1365–1372PubMed Hackert VH, den Heijer T, Oudkerk M et al. (2002) Hippocampal head size associated with verbal memory performance in nondemented elderly. Neuroimage 17:1365–1372PubMed
21.
go back to reference Maunoury C, Michot JL, Caillet H et al. (1996) Specificity of temporal amygdala atrophy in Alzheimer’s disease: quantitative assessment with magnetic resonance imaging. Dementia 7:10–14PubMed Maunoury C, Michot JL, Caillet H et al. (1996) Specificity of temporal amygdala atrophy in Alzheimer’s disease: quantitative assessment with magnetic resonance imaging. Dementia 7:10–14PubMed
22.
go back to reference UNESCO: International Standard Classification of Education (ISCED). Document 19C/3. Paris, 1976 UNESCO: International Standard Classification of Education (ISCED). Document 19C/3. Paris, 1976
23.
go back to reference Vermeer SE, den Heijer T, Koudstaal PJ et al. (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34:392–396PubMed Vermeer SE, den Heijer T, Koudstaal PJ et al. (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34:392–396PubMed
24.
go back to reference Slooter AJC, Cruts M, Kalmijn S et al. (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55:964–968PubMed Slooter AJC, Cruts M, Kalmijn S et al. (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55:964–968PubMed
25.
go back to reference Farrer LA, Cupples LA, Haines JL et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349–1356PubMed Farrer LA, Cupples LA, Haines JL et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349–1356PubMed
26.
go back to reference Bots ML, Hoes AW, Koudstaal PJ et al. (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96:1432–1437PubMed Bots ML, Hoes AW, Koudstaal PJ et al. (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96:1432–1437PubMed
27.
go back to reference Mooy JM, Grootenhuis PA, de Vries H et al. (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273PubMed Mooy JM, Grootenhuis PA, de Vries H et al. (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273PubMed
28.
go back to reference Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965PubMed Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965PubMed
29.
go back to reference Leibson CL, Rocca WA, Hanson VA et al. (1997) The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci 826:422–427PubMed Leibson CL, Rocca WA, Hanson VA et al. (1997) The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci 826:422–427PubMed
30.
go back to reference Brayne C, Gill C, Huppert FA et al. (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9:175–180PubMed Brayne C, Gill C, Huppert FA et al. (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9:175–180PubMed
31.
go back to reference Yoshitake T, Kiyohara Y, Kato I et al. (1995) Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45:1161–1168PubMed Yoshitake T, Kiyohara Y, Kato I et al. (1995) Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45:1161–1168PubMed
32.
go back to reference Luchsinger JA, Tang MX, Stern Y et al. (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641PubMed Luchsinger JA, Tang MX, Stern Y et al. (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641PubMed
33.
go back to reference MacKnight C, Rockwood K, Awalt E et al. (2002) Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14:77–83PubMed MacKnight C, Rockwood K, Awalt E et al. (2002) Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14:77–83PubMed
34.
go back to reference Curb JD, Rodriguez BL, Abbott RD et al. (1999) Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 52:971–975PubMed Curb JD, Rodriguez BL, Abbott RD et al. (1999) Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 52:971–975PubMed
35.
go back to reference Tariot PN, Ogden MA, Cox C et al. (1999) Diabetes and dementia in long-term care. J Am Geriatr Soc 47:423–429PubMed Tariot PN, Ogden MA, Cox C et al. (1999) Diabetes and dementia in long-term care. J Am Geriatr Soc 47:423–429PubMed
36.
go back to reference Bobinski M, de Leon MJ, Wegiel J et al. (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 95:721–725PubMed Bobinski M, de Leon MJ, Wegiel J et al. (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 95:721–725PubMed
37.
go back to reference Petersen RC, Smith GE, Ivnik RJ et al. (1994) Memory function in very early Alzheimer’s disease. Neurology 44:867–872PubMed Petersen RC, Smith GE, Ivnik RJ et al. (1994) Memory function in very early Alzheimer’s disease. Neurology 44:867–872PubMed
38.
go back to reference Petersen RC, Jack CR Jr, Xu YC et al. (2000) Memory and MRI-based hippocampal volumes in aging and AD. Neurology 54:581–587PubMed Petersen RC, Jack CR Jr, Xu YC et al. (2000) Memory and MRI-based hippocampal volumes in aging and AD. Neurology 54:581–587PubMed
39.
go back to reference Convit A, Wolf OT, Tarshish C et al. (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022PubMed Convit A, Wolf OT, Tarshish C et al. (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022PubMed
40.
go back to reference Heitner J, Dickson D (1997) Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49:1306–1311PubMed Heitner J, Dickson D (1997) Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49:1306–1311PubMed
41.
go back to reference Münch G, Schinzel R, Loske C et al. (1998) Alzheimer’s disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439–461PubMed Münch G, Schinzel R, Loske C et al. (1998) Alzheimer’s disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439–461PubMed
42.
go back to reference Ledesma MD, Bonay P, Colaco C et al. (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269:21614–21619PubMed Ledesma MD, Bonay P, Colaco C et al. (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269:21614–21619PubMed
43.
go back to reference Kuusisto J, Koivisto K, Mykkänen L et al. (1997) Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 315:1045–1049PubMed Kuusisto J, Koivisto K, Mykkänen L et al. (1997) Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 315:1045–1049PubMed
44.
go back to reference Craft S, Peskind E, Schwartz MW et al. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50:164–168PubMed Craft S, Peskind E, Schwartz MW et al. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50:164–168PubMed
45.
go back to reference Frölich L, Blum-Degen D, Bernstein HG et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 105:423–438PubMed Frölich L, Blum-Degen D, Bernstein HG et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 105:423–438PubMed
46.
go back to reference Liolitsa D, Powell J, Lovestone S (2002) Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 73:261–266PubMed Liolitsa D, Powell J, Lovestone S (2002) Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 73:261–266PubMed
47.
go back to reference Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177:125–134PubMed Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177:125–134PubMed
48.
go back to reference Kurochkin IV (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26:421–425PubMed Kurochkin IV (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26:421–425PubMed
49.
go back to reference Farris W, Mansourian S, Chang Y et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100:4162–4167PubMed Farris W, Mansourian S, Chang Y et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100:4162–4167PubMed
50.
go back to reference Frölich L, Blum-Degen D, Riederer P et al. (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer’s disease. Ann NY Acad Sci 893:290–293PubMed Frölich L, Blum-Degen D, Riederer P et al. (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer’s disease. Ann NY Acad Sci 893:290–293PubMed
51.
go back to reference Schulingkamp RJ, Pagano TC, Hung D et al. (2000) Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24:855–872PubMed Schulingkamp RJ, Pagano TC, Hung D et al. (2000) Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24:855–872PubMed
Metadata
Title
Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI
Authors
T. den Heijer
S. E. Vermeer
E. J. van Dijk
N. D. Prins
P. J. Koudstaal
A. Hofman
Dr. M. M. B. Breteler
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1235-0

Other articles of this Issue 12/2003

Diabetologia 12/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.